{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:40:37Z","timestamp":1792100437558,"version":"4.4.0"},"reference-count":84,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCR"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>\u03b2-blockers have been widely utilized as a part of acute myocardial infarction (AMI)\ntreatment for the past 40 years. Patients receiving \u03b2-adrenergic blockers for an extended period following\nmyocardial infarction have a higher chance of surviving. Although many patients benefited\nfrom \u03b2-blockers, many do not, including those with myocardial infarction, left ventricle dysfunction,\nchronic pulmonary disease, and elderly people. In individuals with the post-acute coronary\nsyndrome and normal left ventricular ejection fraction (LVEF), the appropriate duration of betablocker\ntherapy is still unknown. There is also no time limit for those without angina and those\nwho do not need \u03b2-blockers for arrhythmia or hypertension. Interestingly, \u03b2-blockers have been\nprescribed for more than four decades. The novel mechanism of action on cellular compartments\nhas been found continually, which opens a new way for their potential application in cardiac failure\nand other cardiac events like post-myocardial infarction. Here, in this review, we studied \u03b2-blocker\nusage in these circumstances and the current recommendations for \u03b2-blocker use from clinical\npractice guidelines.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573403x19666230111143901","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T06:16:45Z","timestamp":1673590605000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Role of \u03b2-blockers in Preventing Heart Failure and Major Adverse\nCardiac Events Post Myocardial Infarction"],"prefix":"10.2174","volume":"19","author":[{"given":"Nishant","family":"Johri","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Teerthanker Mahaveer College of Pharmacy, Moradabad, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithpal S.","family":"Matreja","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Teerthanker Mahaveer Medical College and Research Centre, Moradabad, Uttar\nPradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Maurya","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Teerthanker Mahaveer College of Pharmacy, Moradabad, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Varshney","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Teerthanker Mahaveer College of Pharmacy, Moradabad, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Smritigandha","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Teerthanker Mahaveer College of Pharmacy, Moradabad, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"Roth G.A.","year":"2020","unstructured":"Roth G.A.; Mensah G.A.; Johnson C.O.; Global burden of cardiovascular diseases and risk factors, 1990\u20132019. J Am Coll Cardiol 2020,76(25),2982-3021","journal-title":"J Am Coll Cardiol"},{"key":"ref=2","first-page":"CD012565","volume":"11","author":"Safi S.","year":"2021","unstructured":"Safi S.; Sethi N.J.; Korang S.K.; Beta-blockers in patients without heart failure after myocardial infarction. Cochrane Database Syst Rev 2021,11(11),CD012565","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1186\/s12889-017-4477-3","volume":"17","author":"Aminde L.N.","year":"2017","unstructured":"Aminde L.N.; Takah N.; Ngwasiri C.; Population awareness of cardiovascular disease and its risk factors in Buea, Cameroon. BMC Public Health 2017,17(1),545","journal-title":"BMC Public Health"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","volume":"141","author":"Virani S.S.","year":"2020","unstructured":"Virani S.S.; Alonso A.; Benjamin E.J.; Heart disease and stroke statistics-2020 update: A report from the american heart association. Circulation 2020,141(9),e139-e596","journal-title":"Circulation"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.amjhyper.2005.09.010","volume":"18","author":"Hollenberg N.","year":"2005","unstructured":"Hollenberg N.; The role of \u03b2-blockers as a cornerstone of cardiovascular therapy. Am J Hypertens 2005,18(12),165-168","journal-title":"Am J Hypertens"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000505474","volume":"5","author":"Eriksen-Volnes T","year":"2020","unstructured":"Eriksen-Volnes T; Westheim A; Gullestad L; Slind EK; Grundtvig M; \u03b2-Blocker doses and heart rate in patients with heart failure: Results from the national norwegian heart failure registry. Biomed Hub 2020,5(1),1-10","journal-title":"Biomed Hub"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"e000230","DOI":"10.1136\/openhrt-2014-000230","volume":"2","author":"DiNicolantonio JJ","year":"2015","unstructured":"DiNicolantonio JJ; Fares H; Niazi AK; \u03b2-blockers in hypertension, diabetes, heart failure and acute myocardial infarction: A review of the literature. Open Heart 2015,2(1),e000230","journal-title":"Open Heart"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1093\/eurheartj\/ehaa436","volume":"41","author":"Harari R.","year":"2020","unstructured":"Harari R.; Bangalore S.; Beta-blockers after acute myocardial infarction: An old drug in urgent need of new evidence! Eur Heart J 2020,41(37),3530-3532","journal-title":"Eur Heart J"},{"key":"ref=9","author":"Boyette L.C.","year":"2022","unstructured":"Boyette L.C.; Manna B.;  Physiology, myocardial oxygen demand StatPearls 2022","journal-title":"Physiology, myocardial oxygen demand StatPearls"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1136\/heartjnl-2015-307855","volume":"102","author":"Bulluck H.","year":"2016","unstructured":"Bulluck H.; Yellon D.M.; Hausenloy D.J.; Reducing myocardial infarct size: Challenges and future opportunities. Heart 2016,102(5),341-348","journal-title":"Heart"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.3389\/fimmu.2018.02031","volume":"9","author":"Fioranelli M.","year":"2018","unstructured":"Fioranelli M.; Bottaccioli A.G.; Bottaccioli F.; Bianchi M.; Rovesti M.; Roccia M.G.; Stress and inflammation in coronary artery disease: A review psychoneuroendocrineimmunology-based. Front Immunol 2018,9,2031","journal-title":"Front Immunol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1161\/CIR.0000000000000549","volume":"138","author":"Al-Khatib S.M.","year":"2018","unstructured":"Al-Khatib S.M.; Stevenson W.G.; Ackerman M.J.; 2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation 2018,138(13),e272-e391","journal-title":"Circulation"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/bjaed\/mkv056","volume":"16","author":"Harris P.","year":"2016","unstructured":"Harris P.; Lysitsas D.; Ventricular arrhythmias and sudden cardiac death. BJA Educ 2016,16(7),221-229","journal-title":"BJA Educ"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jacc.2014.04.042","volume":"64","author":"Andersson C","year":"2014","unstructured":"Andersson C; Shilane D; Go AS; \u03b2-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease. J Am Coll Cardiol 2014,64(3),247-252","journal-title":"J Am Coll Cardiol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"e0201311","DOI":"10.1371\/journal.pone.0201311","volume":"13","author":"Park J.","year":"2018","unstructured":"Park J.; Kim J.; Kwon J.H.; Association between perioperative \u03b2-blocker use and clinical outcome of non-cardiac surgery in coronary revascularized patients without severe ventricular dysfunction or heart failure. PLoS One 2018,13(8),e0201311","journal-title":"PLoS One"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7861\/clinmedicine.14-6-604","volume":"14","author":"Mistry R.","year":"2014","unstructured":"Mistry R.; Walker D.; Perioperative beta-blockade: Might the baby go out with the bath water? Clin Med 2014,14(6),604-607","journal-title":"Clin Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/jamainternmed.2013.11349","volume":"174","author":"Andersson C.","year":"2014","unstructured":"Andersson C.; M\u00e9rie C.; J\u00f8rgensen M.; Association of \u03b2-blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: A danish nationwide cohort study. JAMA Intern Med 2014,174(3),336-344","journal-title":"JAMA Intern Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1161\/CIRCOUTCOMES.114.001073","volume":"7","author":"Bangalore S","year":"2014","unstructured":"Bangalore S; Bhatt DL; Steg PG; \u03b2-blockers and cardiovascular events in patients with and without myocardial infarction: Post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes 2014,7(6),872-881","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.cjca.2013.12.001","volume":"30","author":"Poirier L.","year":"2014","unstructured":"Poirier L.; Tobe S.W.; Contemporary use of \u03b2-blockers: Clinical relevance of subclassification. Can J Cardiol 2014,30(5),S9-S15","journal-title":"Can J Cardiol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1186\/s13063-020-4214-6","volume":"21","author":"Kristensen A.M.D.","year":"2020","unstructured":"Kristensen A.M.D.; Bovin A.; Zwisler A.D.; Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: Study protocol for a randomized controlled trial. Trials 2020,21(1),415","journal-title":"Trials"},{"key":"ref=21","first-page":"231","volume":"14","author":"Boudonas GE","year":"2010","unstructured":"Boudonas GE; \u03b2-blockers in coronary artery disease management. Hippokratia 2010,14(4),231-235","journal-title":"Hippokratia"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1161\/CIR.0000000000000104","volume":"130","author":"Wijeysundera D.N.","year":"2014","unstructured":"Wijeysundera D.N.; Duncan D.; Nkonde-Price C.; Perioperative beta blockade in noncardiac surgery: A systematic review for the 2014 acc\/aha guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: A report of the american college of cardiology\/american heart association task force on practice guidelines. Circulation 2014,130(24),2246-2264","journal-title":"Circulation"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"JC2","DOI":"10.7326\/ACPJC-2015-162-6-002","volume":"162","author":"Andersson C.","year":"2015","unstructured":"Andersson C.; Review: Perioperative \u03b2-blockers have variable effects on outcomes in cardiac and noncardiac surgery. Ann Intern Med 2015,162(6),JC2","journal-title":"Ann Intern Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.21037\/jtd.2017.10.25","volume":"9","author":"Noble S.","year":"2017","unstructured":"Noble S.; Roffi M.; Routine beta-blocker administration following acute myocardial infarction: Why still an unsolved issue? J Thorac Dis 2017,9(11),4191-4194","journal-title":"J Thorac Dis"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"e007567","DOI":"10.1161\/JAHA.117.007567","volume":"7","author":"Park J.J.","year":"2018","unstructured":"Park J.J.; Kim S.H.; Kang S.H.; Effect of \u03b2\u2010blockers beyond 3 years after acute myocardial infarction. J Am Heart Assoc 2018,7(5),e007567","journal-title":"J Am Heart Assoc"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"22121","DOI":"10.1038\/s41598-020-79214-0","volume":"10","author":"Lee P.H.","year":"2020","unstructured":"Lee P.H.; Park G.M.; Han S.; Beta-blockers provide a differential survival benefit in patients with coronary artery disease undergoing contemporary post-percutaneous coronary intervention management. Sci Rep 2020,10(1),22121","journal-title":"Sci Rep"},{"key":"ref=27","first-page":"12-20","volume":"5","author":"Dahl AM","year":"2019","unstructured":"Dahl AM; Sandven I; Dondo TB; Effect of oral \u03b2 -blocker treatment on mortality in contemporary post-myocardial infarction patients: A systematic review and meta-analysis. Eur Hear J - Cardiovasc Pharmacother 2019,5(1),12-20","journal-title":"Eur Hear J - Cardiovasc Pharmacother"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3389\/fphar.2018.00904","volume":"9","author":"Lucia C.","year":"2018","unstructured":"Lucia C.; Eguchi A.; Koch W.J.; New insights in cardiac \u03b2-adrenergic signaling during heart failure and aging. Front Pharmacol 2018,9,904","journal-title":"Front Pharmacol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"8957","DOI":"10.3390\/ijms22168957","volume":"22","author":"Matarrese P.","year":"2021","unstructured":"Matarrese P.; Maccari S.; Vona R.; Gambardella L.; Stati T.; Marano G.; Role of \u03b2-adrenergic receptors and estrogen in cardiac repair after myocardial infarction: An overview. Int J Mol Sci 2021,22(16),8957","journal-title":"Int J Mol Sci"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"16598","DOI":"10.1073\/pnas.1419129111","volume":"111","author":"Fu Y.","year":"2014","unstructured":"Fu Y.; Westenbroek R.E.; Scheuer T.; Catterall W.A.; Basal and \u03b2-adrenergic regulation of the cardiac calcium channel CaV 1.2 requires phosphorylation of serine 1700. Proc Natl Acad Sci 2014,111(46),16598-16603","journal-title":"Proc Natl Acad Sci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3389\/fgene.2018.00560","volume":"9","author":"Katsarou M.S.","year":"2018","unstructured":"Katsarou M.S.; Karathanasopoulou A.; Andrianopoulou A.; Beta 1, beta 2 and beta 3 adrenergic receptor gene polymorphisms in a southeastern European population. Front Genet 2018,9,560","journal-title":"Front Genet"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/bph.14552","volume":"176","author":"Dal Monte M","year":"2019","unstructured":"Dal Monte M; Calvani M; Cammalleri M; Favre C; Filippi L; Bagnoli P.; \u03b2 \u2010Adrenoceptors as drug targets in melanoma: Novel preclinical evidence for a role of \u03b2 \u2010adrenoceptors. Br J Pharmacol 2019,176(14),2496-2508","journal-title":"Br J Pharmacol"},{"key":"ref=33","author":"Abosamak N.E.R.","year":"2022","unstructured":"Abosamak N.E.R.; Shahin M.H.;  Beta 2 receptor agonists\/antagonists StatPearls 2022","journal-title":"Beta 2 receptor agonists\/antagonists StatPearls"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"10465","DOI":"10.1038\/s41598-020-67342-6","volume":"10","author":"Porcelli L.","year":"2020","unstructured":"Porcelli L.; Garofoli M.; Di Fonte R.; The \u03b2-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: A pilot study. Sci Rep 2020,10(1),10465","journal-title":"Sci Rep"},{"key":"ref=35","author":"Alhayek S.","year":"2022","unstructured":"Alhayek S.; Preuss C.V.;  Beta 1 receptors StatPearls 2022","journal-title":"Beta 1 receptors StatPearls"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"588724","DOI":"10.3389\/fimmu.2020.588724","volume":"11","author":"Barbieri A.","year":"2020","unstructured":"Barbieri A.; Robinson N.; Palma G.; Maurea N.; Desiderio V.; Botti G.; Can beta-2-adrenergic pathway be a new target to combat sars-cov-2 hyperinflammatory syndrome?-lessons learned from cancer. Front Immunol 2020,11,588724","journal-title":"Front Immunol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/s41598-017-01047-1","volume":"7","author":"Szentirmai \u00c9.","year":"2017","unstructured":"Szentirmai \u00c9.; Kap\u00e1s L.; The role of the brown adipose tissue in \u03b23-adrenergic receptor activation-induced sleep, metabolic and feeding responses. Sci Rep 2017,7(1),958","journal-title":"Sci Rep"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"e153357","DOI":"10.1172\/JCI153357","volume":"132","author":"Valentine JM","year":"2022","unstructured":"Valentine JM; Ahmadian M; Keinan O; \u03b23-adrenergic receptor downregulation leads to adipocyte catecholamine resistance in obesity. J Clin Invest 2022,132(2),e153357","journal-title":"J Clin Invest"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3389\/fendo.2018.00249","volume":"9","author":"Merlin J.","year":"2018","unstructured":"Merlin J.; Sato M.; Chia L.Y.; Rosiglitazone and a \u03b23-adrenoceptor agonist are both required for functional browning of white adipocytes in culture. Front Endocrinol 2018,9,249","journal-title":"Front Endocrinol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3389\/fphys.2013.00323","volume":"4","author":"Barrese V.","year":"2013","unstructured":"Barrese V.; Taglialatela M.; New advances in beta-blocker therapy in heart failure. Front Physiol 2013,4,323","journal-title":"Front Physiol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"e5285","DOI":"10.1590\/1414-431x20165285","volume":"49","author":"L\u00f3pez-Canales O.A.","year":"2016","unstructured":"L\u00f3pez-Canales O.A.; Castillo-Hernandez M.C.; Vargas-Robles H.; Rios A.; L\u00f3pez-Canales J.S.; Escalante B.; Role of adenylyl cyclase in reduced \u03b2-adrenoceptor-mediated vasorelaxation during maturation. Braz J Med Biol Res 2016,49(7),e5285","journal-title":"Braz J Med Biol Res"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"23096","DOI":"10.1073\/pnas.2009786117","volume":"117","author":"Ma X.","year":"2020","unstructured":"Ma X.; Hu Y.; Batebi H.; Analysis of \u03b22 AR-Gs and \u03b22 AR-Gi complex formation by NMR spectroscopy. Proc Natl Acad Sci 2020,117(37),23096-23105","journal-title":"Proc Natl Acad Sci"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1111\/j.1476-5381.2009.00602.x","volume":"159","author":"Evans B.A.","year":"2010","unstructured":"Evans B.A.; Sato M.; Sarwar M.; Hutchinson D.S.; Summers R.J.; Ligand-directed signalling at \u03b2-adrenoceptors. Br J Pharmacol 2010,159(5),1022-1038","journal-title":"Br J Pharmacol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40164-020-00191-1","volume":"9","author":"Zhang H.","year":"2020","unstructured":"Zhang H.; Kong Q.; Wang J.; Jiang Y.; Hua H.; Complex roles of cAMP\u2013PKA\u2013CREB signaling in cancer. Exp Hematol Oncol 2020,9(1),32","journal-title":"Exp Hematol Oncol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3390\/cells10040875","volume":"10","author":"Thiel G.","year":"2021","unstructured":"Thiel G.; Schmidt T.; R\u00f6ssler O.G.; Ca2+ Microdomains, calcineurin and the regulation of gene transcription. Cells 2021,10(4),875","journal-title":"Cells"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.physbeh.2017.03.040","volume":"176","author":"Wen A.Y.","year":"2017","unstructured":"Wen A.Y.; Sakamoto K.M.; Miller L.S.; The role of the transcription factor creb in immune function. Physiol Behav 2017,176(3),139-148","journal-title":"Physiol Behav"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"a004242","DOI":"10.1101\/cshperspect.a004242","volume":"3","author":"Fearnley C.J.","year":"2011","unstructured":"Fearnley C.J.; Roderick H.L.; Bootman M.D.; Calcium signaling in cardiac myocytes. Cold Spring Harb Perspect Biol 2011,3(11),a004242","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref=48","first-page":"711","volume":"78","author":"Lipskaia L.","year":"2012","unstructured":"Lipskaia L.; Chemaly E.R.; Hadri L.; Lompre A.M.; Hajjar R.J.; Sarcoplasmic reticulum Ca2+ ATPase as a therapeutic target for heart failure. Bone 2012,78(2),711-716","journal-title":"Bone"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"F18","DOI":"10.1016\/0002-9149(87)90036-1","volume":"59","author":"Taylor S.H.","year":"1987","unstructured":"Taylor S.H.; Role of cardioselectivity and intrinsic sympathomimetic activity in beta-blocking drugs in cardiovascular disease. Am J Cardiol 1987,59(13),F18-F20","journal-title":"Am J Cardiol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1185\/03007999109111659","volume":"12","author":"Cruickshank J.M.","year":"1991","unstructured":"Cruickshank J.M.; McAinsh J.; Atenolol and ischaemic heart disease: An overview. Curr Med Res Opin 1991,12(8),485-496","journal-title":"Curr Med Res Opin"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1136\/bmj.39185.440382.47","volume":"334","author":"Ong HT","year":"2007","unstructured":"Ong HT;  \u03b2 -blockers in hypertension and cardiovascular disease. BMJ 2007,334(7600),946-949","journal-title":"BMJ"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"247-56","DOI":"10.1023\/A:1007735729121","volume":"11","author":"Ruffolo RR","year":"1997","unstructured":"Ruffolo RR; Feuerstein GZ; Pharmacology of carvedilol: Rationale for use in hypertension, coronary artery disease, and congestive heart failure. Cardiovasc Drugs Ther 1997,11(1+),247-56","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1080\/03007995.2018.1479245","volume":"34","author":"Grassi G.","year":"2018","unstructured":"Grassi G.; Metoprolol in the treatment of cardiovascular disease: A critical reappraisal. Curr Med Res Opin 2018,34(9),1635-1643","journal-title":"Curr Med Res Opin"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12916-017-0781-0","volume":"15","author":"Morales D.R.","year":"2017","unstructured":"Morales D.R.; Lipworth B.J.; Donnan P.T.; Jackson C.; Guthrie B.; Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study. BMC Med 2017,15(1),18","journal-title":"BMC Med"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/jhh.2017.8","volume":"31","author":"Coats A.","year":"2017","unstructured":"Coats A.; Jain S.; Protective effects of nebivolol from oxidative stress to prevent hypertension-related target organ damage. J Hum Hypertens 2017,31(6),376-381","journal-title":"J Hum Hypertens"},{"key":"ref=56","author":"Shahrokhi M.","year":"2022","unstructured":"Shahrokhi M.; Gupta V.;  Propranolol StatPearls 2022","journal-title":"Propranolol StatPearls"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jacc.2007.04.060","volume":"50","author":"Bangalore S.","year":"2007","unstructured":"Bangalore S.; Messerli F.H.; Kostis J.B.; Pepine C.J.; Cardiovascular protection using beta-blockers: A critical review of the evidence. J Am Coll Cardiol 2007,50(7),563-572","journal-title":"J Am Coll Cardiol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2046-4053-2-7","volume":"2","author":"Kotecha D.","year":"2013","unstructured":"Kotecha D.; Manzano L.; Altman D.G.; Individual patient data meta-analysis of beta-blockers in heart failure: Rationale and design. Syst Rev 2013,2(1),7","journal-title":"Syst Rev"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1161\/CIRCRESAHA.119.313572","volume":"124","author":"Pfeffer M.A.","year":"2019","unstructured":"Pfeffer M.A.; Shah A.M.; Borlaug B.A.; Heart failure with preserved ejection fraction in perspective. Circ Res 2019,124(11),1598-1617","journal-title":"Circ Res"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s11886-002-0048-y","volume":"4","author":"Greenberg B.H.","year":"2002","unstructured":"Greenberg B.H.; Heart failure epidemic. Curr Cardiol Rep 2002,4(3),185","journal-title":"Curr Cardiol Rep"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12916-020-01564-3","volume":"18","author":"Ziff O.J.","year":"2020","unstructured":"Ziff O.J.; Samra M.; Howard J.P.; Beta-blocker efficacy across different cardiovascular indications: An umbrella review and meta-analytic assessment. BMC Med 2020,18(1),103","journal-title":"BMC Med"},{"key":"ref=62","first-page":"13","volume":"95","author":"Chavey W.E.","year":"2017","unstructured":"Chavey W.E.; Hogikyan R.V.; Van Harrison R.; Nicklas J.M.; Heart failure due to reduced ejection fraction: Medical management. Am Fam Physician 2017,95(1),13-20","journal-title":"Am Fam Physician"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"665202","DOI":"10.3389\/fcvm.2021.665202","volume":"8","author":"Faragli A.","year":"2021","unstructured":"Faragli A.; Tano G.D.; Carlini C.D.; In-hospital heart rate reduction with beta blockers and ivabradine early after recovery in patients with acute decompensated heart failure reduces short-term mortality and rehospitalization. Front Cardiovasc Med 2021,8,665202","journal-title":"Front Cardiovasc Med"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3390\/jcdd8090101","volume":"8","author":"Masarone D.","year":"2021","unstructured":"Masarone D.; Martucci M.L.; Errigo V.; Pacileo G.; The use of \u03b2-blockers in heart failure with reduced ejection fraction. J Cardiovasc Dev Dis 2021,8(9),101","journal-title":"J Cardiovasc Dev Dis"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"718","DOI":"10.4065\/84.8.718","volume":"84","author":"Klapholz M.","year":"2009","unstructured":"Klapholz M.; Beta-blocker use for the stages of heart failure. Mayo Clin Proc 2009,84(8),718-729","journal-title":"Mayo Clin Proc"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1161\/CIRCULATIONAHA.104.500546","volume":"111","author":"Mann D.L.","year":"2005","unstructured":"Mann D.L.; Bristow M.R.; Mechanisms and models in heart failure: The biomechanical model and beyond. Circulation 2005,111(21),2837-2849","journal-title":"Circulation"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"D3","DOI":"10.1093\/ehjsupp\/4.suppl_D.D3","volume":"4","author":"Ferrara R.","year":"2002","unstructured":"Ferrara R.; Mastrorilli F.; Pasanisi G.; Neurohormonal modulation in chronic heart failure. Eur Heart J Suppl 2002,4,D3-D11","journal-title":"Eur Heart J Suppl"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3389\/fphys.2014.00246","volume":"5","author":"de Lucia C.","year":"2014","unstructured":"de Lucia C.; Femminella G.D.; Gambino G.; Adrenal adrenoceptors in heart failure. Front Physiol 2014,5,246","journal-title":"Front Physiol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3389\/fphys.2013.00396","volume":"4","author":"Ferrara N","year":"2014","unstructured":"Ferrara N; Komici K; Corbi G; \u03b2-adrenergic receptor responsiveness in aging heart and clinical implications. Front Physiol 2014,4,396","journal-title":"Front Physiol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1161\/CIRCRESAHA.111.245092","volume":"109","author":"Bristow M.R.","year":"2011","unstructured":"Bristow M.R.; Treatment of chronic heart failure with \u03b2-adrenergic receptor antagonists: A convergence of receptor pharmacology and clinical cardiology. Circ Res 2011,109(10),1176-1194","journal-title":"Circ Res"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/j.1527-5299.2003.01446.x","volume":"9","author":"Maack C.","year":"2003","unstructured":"Maack C.; Elter T.; B\u00f6hm M.; Beta-blocker treatment of chronic heart failure: Comparison of carvedilol and metoprolol. Congest Heart Fail 2003,9(5),263-270","journal-title":"Congest Heart Fail"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jchf.2017.09.015","volume":"6","author":"Bahit M.C.","year":"2018","unstructured":"Bahit M.C.; Kochar A.; Granger C.B.; Post-myocardial infarction heart failure. JACC Heart Fail 2018,6(3),179-186","journal-title":"JACC Heart Fail"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","volume":"64","author":"Amsterdam E.A.","year":"2014","unstructured":"Amsterdam E.A.; Wenger N.K.; Brindis R.G.; 2014 AHA\/ACC guideline for the management of patients with non\u2013st-elevation acute coronary syndromes. J Am Coll Cardiol 2014,64(24),e139-e228","journal-title":"J Am Coll Cardiol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","volume":"124","author":"Smith S.C.","year":"2011","unstructured":"Smith S.C.; Benjamin E.J.; Bonow R.O.; AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update. Circulation 2011,124(22),2458-2473","journal-title":"Circulation"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi M.","year":"2016","unstructured":"Roffi M.; Patrono C.; Collet J.P.; 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation. Eur Heart J 2016,37(3),267-315","journal-title":"Eur Heart J"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.amjmed.2014.05.032","volume":"127","author":"Bangalore S.","year":"2014","unstructured":"Bangalore S.; Makani H.; Radford M.; Clinical outcomes with \u03b2-blockers for myocardial infarction: A meta-analysis of randomized trials. Am J Med 2014,127(10),939-953","journal-title":"Am J Med"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1161\/CIRCULATIONAHA.113.003653","volume":"128","author":"Ibanez B.","year":"2013","unstructured":"Ibanez B.; Macaya C.; S\u00e1nchez-Brunete V.; Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: The effect of metoprolol in cardioprotection during an acute myocardial infarction (METOCARD-CNIC) trial. Circulation 2013,128(14),1495-1503","journal-title":"Circulation"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1016\/j.jacc.2014.03.014","volume":"63","author":"Pizarro G.","year":"2014","unstructured":"Pizarro G.; Fern\u00e1ndez-Friera L.; Fuster V.; Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: Results from the METOCARD-CNIC trial (effect of metoprolol in cardioprotection during an acute myocardial infarction). J Am Coll Cardiol 2014,63(22),2356-2362","journal-title":"J Am Coll Cardiol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/j.jacc.2016.03.522","volume":"67","author":"Roolvink V.","year":"2016","unstructured":"Roolvink V.; Ib\u00e1\u00f1ez B.; Ottervanger J.P.; early intravenous beta-blockers in patients with st-segment elevation myocardial infarction before primary percutaneous coronary intervention. J Am Coll Cardiol EARLY-BAMI investigators2016,67(23),2705-2715","journal-title":"J Am Coll Cardiol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"14780","DOI":"10.1038\/ncomms14780","volume":"8","author":"Garc\u00eda-Prieto J.","year":"2017","unstructured":"Garc\u00eda-Prieto J.; Villena-Guti\u00e9rrez R.; G\u00f3mez M.; Neutrophil stunning by metoprolol reduces infarct size. Nat Commun 2017,8(1),14780","journal-title":"Nat Commun"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/joim.12141","volume":"275","author":"Wikstrand J.","year":"2014","unstructured":"Wikstrand J.; Wedel H.; Castagno D.; McMurray J.J.V.; The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: Results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF. J Intern Med 2014,275(2),134-143","journal-title":"J Intern Med"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s40256-017-0221-8","volume":"17","author":"D\u00e9zsi C.A.","year":"2017","unstructured":"D\u00e9zsi C.A.; Szentes V.; The real role of \u03b2-blockers in daily cardiovascular therapy. Am J Cardiovasc Drugs 2017,17(5),361-373","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1080\/17476348.2019.1649147","volume":"13","author":"Tiotiu A.","year":"2019","unstructured":"Tiotiu A.; Novakova P.; Kowal K.; Beta-blockers in asthma: Myth and reality. Expert Rev Respir Med 2019,13(9),815-822","journal-title":"Expert Rev Respir Med"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"3572","DOI":"10.1016\/j.ijcard.2013.05.068","volume":"168","author":"Barron A.J.","year":"2013","unstructured":"Barron A.J.; Zaman N.; Cole G.D.; Wensel R.; Okonko D.O.; Francis D.P.; Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: Recommendations for patient information. Int J Cardiol 2013,168(4),3572-3579","journal-title":"Int J Cardiol"}],"container-title":["Current Cardiology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573403X19666230111143901","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/212591\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573403X19666230111143901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T16:07:56Z","timestamp":1692288476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/212591\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573403x19666230111143901","relation":{},"ISSN":["1573-403X"],"issn-type":[{"value":"1573-403X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-05-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e110123212591"}}